Sanofi adds another bolt-on acquisition in what is turning out to be a busy year for the French pharma titan.
Compare KDMN Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
Kadmon Holdings, Inc.
News & Analysis: Kadmon Holdings, Inc.
The developmental biotech reported quarterly results and gave investors updates on its drug pipeline.
The company reported positive results from a clinical trial for one of its most promising pipeline candidates.
Positive clinical trial results for the biopharmaceutical company's lead candidate, KD025, are driving investors' optimism.
Hardly anyone's heard of either of these drugmakers, but some analysts think they could be top performers.
Investors are excited about the biotech's new infusion of cash.
Sometimes the devil is in the details.
The broader market was in the green, but these stocks fell. Find out why.